311 related articles for article (PubMed ID: 22644716)
1. Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis.
Stobaugh DJ; Deepak P; Thorpe M; Hannon B; Ehrenpreis ED
Inflamm Bowel Dis; 2013 Feb; 19(2):301-8. PubMed ID: 22644716
[TBL] [Abstract][Full Text] [Related]
2. A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol).
Thorpe MP; Ehrenpreis ED; Putt KS; Hannon B
Aliment Pharmacol Ther; 2009 Jun; 29(11):1193-201. PubMed ID: 19222409
[TBL] [Abstract][Full Text] [Related]
3. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
Harris MS; Lichtenstein GR
Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194
[TBL] [Abstract][Full Text] [Related]
4. A dynamic model of once-daily 5-aminosalicylic acid predicts clinical efficacy.
Parakkal D; Ehrenpreis ED; Thorpe MP; Putt KS; Hannon B
World J Gastroenterol; 2010 Jan; 16(1):136-7. PubMed ID: 20039462
[TBL] [Abstract][Full Text] [Related]
5. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis.
Campieri M; Corbelli C; Gionchetti P; Brignola C; Belluzzi A; Di Febo G; Zagni P; Brunetti G; Miglioli M; Barbara L
Dig Dis Sci; 1992 Dec; 37(12):1890-7. PubMed ID: 1473437
[TBL] [Abstract][Full Text] [Related]
6. Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis.
Gionchetti P; Venturi A; Rizzello F; Corbelli C; Fanti S; Ferretti M; Boschi S; Miglioli M; Campieri M
Aliment Pharmacol Ther; 1997 Aug; 11(4):679-84. PubMed ID: 9305475
[TBL] [Abstract][Full Text] [Related]
7. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.
Lichtenstein GR; Kamm MA
Aliment Pharmacol Ther; 2008 Sep; 28(6):663-73. PubMed ID: 18532992
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats.
Li J; Chen C; Cao XN; Wang GH; Hu JB; Wang J
J Huazhong Univ Sci Technolog Med Sci; 2014 Feb; 34(1):59-65. PubMed ID: 24496680
[TBL] [Abstract][Full Text] [Related]
9. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
[TBL] [Abstract][Full Text] [Related]
10. [Drug therapy for ulcerative colitis: salazosulfapyridine and 5-ASA].
Jo Y; Matsumoto T; Iida M
Nihon Rinsho; 2005 May; 63(5):820-4. PubMed ID: 15881176
[TBL] [Abstract][Full Text] [Related]
11. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.
D'Incà R; Paccagnella M; Cardin R; Pathak S; Baldo V; Giron MC; Sturniolo GC
World J Gastroenterol; 2013 Sep; 19(34):5665-70. PubMed ID: 24039359
[TBL] [Abstract][Full Text] [Related]
12. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment.
Frieri G; Pimpo MT; Palumbo GC; Onori L; Viscido A; Latella G; Galletti B; Pantaleoni GC; Caprilli R
Aliment Pharmacol Ther; 1999 Nov; 13(11):1413-7. PubMed ID: 10571596
[TBL] [Abstract][Full Text] [Related]
13. MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.
Hu MY; Peppercorn MA
Expert Opin Pharmacother; 2008 Apr; 9(6):1049-58. PubMed ID: 18377346
[TBL] [Abstract][Full Text] [Related]
14. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
[TBL] [Abstract][Full Text] [Related]
15. Standard treatment of ulcerative colitis.
Gionchetti P; Rizzello F; Habal F; Morselli C; Amadini C; Romagnoli R; Campieri M
Dig Dis; 2003; 21(2):157-67. PubMed ID: 14571113
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficiency of different enemas on patients with distal ulcerative colitis.
Zhang Y; Chen D; Wang F; Li X; Xue X; Jiang M; Xu B; Chu Y; Wang W; Wu K; Mao R; Shen J; Yang S; Liang J
Cell Prolif; 2019 Mar; 52(2):e12559. PubMed ID: 30659678
[TBL] [Abstract][Full Text] [Related]
17. Colonic spreading of a non-chlorofluorocarbon mesalazine rectal foam enema in patients with quiescent ulcerative colitis.
Wilding IR; Kenyon CJ; Chauhan S; Hooper G; Marshall S; McCracken JS; Staab HJ; Armbrecht J
Aliment Pharmacol Ther; 1995 Apr; 9(2):161-6. PubMed ID: 7605856
[TBL] [Abstract][Full Text] [Related]
18. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Bosworth BP; Sandborn WJ; Rubin DT; Harper JR
Inflamm Bowel Dis; 2016 Aug; 22(8):1881-6. PubMed ID: 27416045
[TBL] [Abstract][Full Text] [Related]
19. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
[TBL] [Abstract][Full Text] [Related]
20. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Kamm MA; Sandborn WJ; Gassull M; Schreiber S; Jackowski L; Butler T; Lyne A; Stephenson D; Palmen M; Joseph RE
Gastroenterology; 2007 Jan; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
